Guselkumab for crohn's disease after bowel surgery
Treatments studied
Part of Digestive system clinical trials.
This study is testing the drug guselkumab (brand name Tremfya) in people with Crohn's disease who have already had surgery to remove a damaged part of their intestine. The goal is to see how well the drug works to keep the disease from coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are 18 years or older
- Have been diagnosed with moderate to severe Crohn's disease
- Have had surgery to remove part of your small and large intestine (ileocolonic resection)
- Do not have severe complications like short bowel syndrome or an abscess
- Do not have an active infection
- Have not had cancer (other than certain skin cancers) in the last 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
This study compares two medicines, Guselkumab and Ustekinumab, for people with Crohn's disease that causes narrowing (strictures) in the bowel. It aims to find which works better to improve symptoms and avoid the need for more procedures.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study tests whether guselkumab (a targeted drug) can effectively treat Crohn's disease in the ileum (last part of the small intestine). You will have ultrasound scans and blood tests to measure your response, which may help find the right dose and monitor for bowel healing.
This study looks at how well guselkumab (Tremfya) works for people with moderate to severe Crohn's disease or ulcerative colitis when used in everyday medical practice. It collects information from patients who are prescribed this medicine to better understand its long-term effects and safety.
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
Hear when a new Crohn's Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.